;

In the Specification

On Page 1 of the enclosed specification, kindly insert the following text at Line 6:

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of, and claims priority to co-pending U.S. Application No. 09/991,028, which was filed on November 20, 2001. This application also claims benefit of U.S. Application Serial No. 09/242,190 (now U.S.P.N. 6,413,544), which was filed on October 4, 1999, which was a '371 of PCT/US97/713599. Lastly, this application claims the benefit of U.S. Provisional Application No. 60/024,386, which was filed on August 19, 1996.

In the Claims

Please cancel claims 1-17 without prejudice.

As noted above, Applicants have cancelled claims 1-17 of this application, and hereby request that calculation of the filing fee for, and initial examination of this application be conducted in connection with the remaining claims, i.e., claims 18-19.

- 18. (New) A composite liposome comprising a first lipid bilayer liposome having an outer surface; a biologically active agent surrounding the outer surface of said first lipid bilayer liposome; and a second lipid bilayer encapsulating the biologically active agent, wherein said composite liposome forms an invaginated vase-like structure.
- 19. (New) The composite liposome of claim 18, wherein the biologically active agent is DNA.

Applicants respectfully request early consideration and allowance of this continuation application.

If the undersigned can be of any assistance in advancing the prosecution of this case, the Examiner is invited to telephone him at the numbers given below.

Respectfully submitted,

Date: April <u>/5</u>, 2004

By:

Gregory B. Butler, Ph.D., Esq.

Reg. No.: 34,558

EDWARDS & ANGELL, LLP

P.O. Box 55874 Boston, MA 02205

Tel: 617-439-4444 Fax: 617-439-4170 Customer No.: 21874